[1]美合日阿依·约麦尔 孟丹心 李益民 黄进.冠状动脉药物洗脱支架植入术后限期行非心脏手术围手术期抗血小板治疗研究进展[J].心血管病学进展,2022,(11):993.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.007]
　Meiheriayi·Yuemaier,MENG Danxin,LI Yimin,et al.Perioperative Antiplatelet Therapy in Non-Cardiac Surgery within A Limited Period A fter Coronary Drug-Eluting Stent Implantation[J].Advances in Cardiovascular Diseases,2022,(11):993.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.007]
点击复制

冠状动脉药物洗脱支架植入术后限期行非心脏手术围手术期抗血小板治疗研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年11期
页码:
993
栏目:
综述
出版日期:
2022-11-25

文章信息/Info

Title:
Perioperative Antiplatelet Therapy in Non-Cardiac Surgery within A Limited Period A fter Coronary Drug-Eluting Stent Implantation
作者:
美合日阿依·约麦尔1 孟丹心1 李益民2 黄进3
(1.南京医科大学附属脑科医院,江苏 南京 210029;2.南京医科大学附属逸夫医院心血管内科,江苏 南京 211166;3.南京医科大学附属脑科医院心内科,江苏 南京 210029)
Author(s):
Meiheriayi·Yuemaier1;  MENG Danxin 1;  LI Yimin2;  HUANG Jin3?
(1.The Affiliated Brain Hospital of Nanjing Medical University,Nanjing 210029,Jiangsu,China; 2. Department of Cardiology,Sir Run Run Hospital,Nanjing Medical University,Nanjing 211166,Jiangsu,China; 3. Department of Cardiology,The Affiliated Brain Hospital of Nanjing Medical University,Nanjing 210029,Jiangsu,China)
关键词:
抗血小板; 经皮冠状动脉介入治疗; 非心脏手术; 桥接治疗
Keywords:
Antiplatelet; Percutaneous coronary intervention; Non-cardiac surgery; Bridging therapy
DOI:
10.16806/j.cnki.issn.1004-3934.2022.11.007
摘要:
心脏支架植入术后常规服用双重抗血小板药是预防术后血栓并发症的基石，同时能有效减少心血管事件的发生，在此期间部分患者需限期行非心脏手术。为寻求其缺血和出血风险达到最佳平衡，现临床上针对此围手术期抗血小板治疗的策略仍有争议。现就 冠状动脉药物洗脱支架植入术后限期行非心脏手术围手术期抗血小板治疗是否需停用和桥接及对应的桥接方案应用及进展做一综述。
Abstract:
Routine use of dual antiplatelet drugs after cardiac stenting is the cornerstone of preventing postoperative thrombosis complications,and can effectively reduce the occurrence of cardiovascular events,during which some patients need to undergo non-cardiac surgery within a limited period. In order to achieve the optimal balance between perioperative ischemia and bleeding risk in these patients,the decision of perioperative antiplatelet therapy is still controversial. This article reviews the application and progress of perioperative antiplatelet discontinuation and bridging in non-cardiac surgery within limited period after coronary drug-eluting stent implantation

参考文献/References:

[1]. 中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等. 冠心病双联抗血小板治疗中国专家共识[J]. 中华心血管病杂志,2021,49(05):432-454.
[2]. Smilowitz NR,Lorin J, Berger JS. Risks of noncardiac surgery early after percutaneous coronary intervention[J]. Am Heart J,2019,217:64-71.
[3]. Hawn MT,Graham LA,Richman JR,et al. The incidence and timing of noncardiac surgery after cardiac stent implantation[J]. J Am Coll Surg,2012,214(4):658-666.
[4]. Kristensen SD,Knuuti J,Saraste A,et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment andmanagement[J]. Kardiol Pol,2014,72(11):857.
[5]. 中国心胸血管麻醉学会非心脏麻醉分会,中国医师协会心血管内科医师分会,中国心血管健康联盟. 抗血栓药物围手术期管理多学科专家共识[J]. 中华医学杂志,2020,100(39):3058-3074.
[6]. Rossini R,Tarantini G,Musumeci G,et al. A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: surgery after stenting 2[J]. JACC Cardiovasc Inte rv,2018,11(5):417-434.
[7]. Gretler DD,Guerciolini R, Williams PJ. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function[J]. Clin T her,2004,26(3):390-398.
[8]. Cao D,Chandiramani R,Capodanno D,et al. Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management[J]. Nat Rev Cardiol,2021,18(1):37-57.
[9]. Walker EA,Dager WE. Bridging with tirofiban during oral antiplatelet interruption: a single‐center case series analysis including patients on hemodialysis[J]. Pharmacotherapy,2017,37(8):888-892.
[10]. Cao D,Levin MA,Sartori S,et al. Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI[J]. J Thromb Thrombolysis,2022,53(2):380-389.
[11]. Costa F,van Klaveren D,James S,et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score:a pooled analysis of individual-patient datasets from clinical trials[J]. Lancet,2017,389(10073):1025-1034.
[12]. Costa F,van Klaveren D,Feres F,et al. Dual antiplatelet therapy duration based?on ischemic and bleeding risks after coronarystenting[J]. J Am Coll Cardiol,2019,73(7):741-754.
[13]. Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165 .
[14]. Levine GN,Bates ER,Bittl JA,et al. 2016 ACC/AHA guideline focusedupdate on duration of dualantiplatelet therapy in patients with coronary artery disease[J]. J Am Coll Cardiol ,2016,68(10):1082-1115.
[15]. Lawton JS,Tamis-Holland JE,Bangalore S,et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2021,145(3):18-114.
[16]. 刘凤林,楼文晖,缪长虹,等. 抗栓治疗患者接受非心脏手术围手术期管理的上海专家共识(2021版)[J]. 上海医学,2021,44(08):537-544.
[17]. Godier A,Fontana P,Motte S,et al. Management of antiplatelet therapy in patients undergoing elective invasive procedures: proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR)[J]. Arch Cardiovasc Dis,2018,111(3):210-223.
[18]. Capodanno D,Musumeci G,Lettieri C,et al. Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery[J]. Thromb Haemost,2015,114(2):423-431.
[19]. Gotoh S,Yasaka M,Nakamura A,et al. Management of antithrombotic agents during surgery or other kinds of medical procedures with bleeding:the MARK study[J]. J Am Heart Assoc ,2020,9(5):e012774.
[20]. Barra ME,Fanikos J,Gerhard-Herman MD,et al. Bridging experience with eptifibatide after stent implantation[J]. Crit Pathw Cardiol,2016,15(3):82-88.

相似文献/References:

[1]袁德山,袁晋青.冠心病患者中基于基因检测的个体化抗血小板治疗最新研究进展[J].心血管病学进展,2019,(6):841.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.001]
　YUAN Deshan,YUAN Jinqing.Individualized Antiplatelet Therapy Based on Gene Testing in Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):841.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.001]
[2]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
　HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(11):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[3]孙伯晨 韩薇.血小板功能检测指导经皮冠脉介入术后抗血小板治疗的研究进展[J].心血管病学进展,2020,(11):1132.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2020.11.000]
[4]贺彩红 荣晶晶 潘宏伟.定量血流分数在急性心肌梗死中的应用进展[J].心血管病学进展,2021,(4):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
　HE Caihong,RONG Jingjing,PAN Hongwei.Progress in the Application of Quantitative Flow Ratio in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(11):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
[5]陈佳仑 李树仁.不同策略血栓抽吸对于急性ST段抬高心肌梗死患者的研究进展[J].心血管病学进展,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
　CHEN Jialun,LI Shuren.Different Strategies of Thrombus Aspiration in Patients with Acute ST Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(11):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
[6]梁晨笛 秦纲.经皮冠状动脉介入诊疗中穿刺路径研究进展[J].心血管病学进展,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
　LIANG Chendi,QIN Gang.Puncture Routes in Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(11):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[7]马兴鸿 汪蕾 方纬.核素心肌显像在冠状动脉慢性完全闭塞临床诊疗中的应用价值[J].心血管病学进展,2022,(4):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
　MA Xinghong,WANG Lei,FANG Wei.Application Value of Radionuclide Myocardial Imaging In the Clinical Diagnosis And Treatment of Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2022,(11):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
[8]张爽 吴娜琼.腔内影像学在冠状动脉支架内再狭窄诊治应用中的研究进展[J].心血管病学进展,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
　ZHANG Shuang,WU Na qiong.Application of Intravascular Imaging in Diagnosis and Treatment of Coronary In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(11):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
[9]管翔 王宇 张成糕 周健 张艺 李庆国.经皮心室辅助装置在复杂高危冠状动脉介入治疗中的应用进展[J].心血管病学进展,2022,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
　GUAN Xiang,WANG Yu,ZHANG Chenggao,et al.Application Progress of Percutaneous Ventricular Assist Device in Complex High-Risk Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(11):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
[10]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
　LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(11):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]

更新日期/Last Update: 2023-01-31